Spinraza Nusinersen 12mg Injection, 1ml-5ml, For Brain Nervous System Medicines, Medicine Type : Allopathic

The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy(SMA), a rare and often fatal genetic disease affecting muscle strength and movement.Biogen,

which is licensing Spinraza from Ionis Pharmaceuticals, said this week that one dose will have a list price of $125, 000. That means the drug will cost $625, 000to $750, 000 to cover the five or six doses needed in the first year, and about$375, 000 annually after that, to cover the necessary three doses a year